Document is current
Any future updates will be listed below
-
Authors
Van de Sande, Bram
Lee, Joon Sang https://orcid.org/0000-0003-0838-6166
Mutasa-Gottgens, Euphemia https://orcid.org/0000-0001-6651-2592
Naughton, Bart https://orcid.org/0000-0002-9121-7445
Bacon, Wendi https://orcid.org/0000-0002-8170-8806
Manning, Jonathan
Wang, Yong https://orcid.org/0000-0001-7183-3737
Pollard, Jack
Mendez, Melissa https://orcid.org/0000-0002-3995-2469
Hill, Jon https://orcid.org/0000-0003-1592-6482
Kumar, Namit https://orcid.org/0000-0002-5084-3490
Cao, Xiaohong https://orcid.org/0000-0002-2275-4060
Chen, Xiao
Khaladkar, Mugdha
Wen, Ji https://orcid.org/0000-0002-3327-5591
Leach, Andrew https://orcid.org/0000-0001-8178-0253
Ferran, Edgardo https://orcid.org/0000-0003-2092-2486
- License Information
-
More Information
Article History
Accepted: 10 March 2023
First Online: 28 April 2023
Competing interests
: N.K. is an employee and shareholder of BMS. M.M. is an employee and shareholder of GSK. B.V.d.S. is an employee and shareholder of UCB Pharma. M.K. is an employee and shareholder of GSK. J.H. is an employee of Boehringer Ingelheim Pharmaceuticals, Inc. B.N. is an employee of Eisai, Inc. J.S.L. is an employee and shareholder of Sanofi. Y.W. was previously a shareholder of BMS. J.P. was previously an employee and shareholder of Sanofi. J.W. is an employee of Pfizer. E.F. is a shareholder of Sanofi and Board Director of Pulmobiotics. A.L. is a GSK shareholder, has consulted for Astex Therapeutics, LifeArc and Syncona and has received research funding from Novo Nordisk and AstraZeneca. X.C. is a former employee and shareholder of AbbVie. E.M.-G., W.B. and J.M. declare no competing interests.
